Application of circulating microRNAs in multiple myeloma

doi:10.3760/cma.j.issn.1673-422X.2018.01.012

Abstract

Yuan Qing, Chen Shaoshui. Application of circulating microRNAs in multiple myeloma[J]. Journal of International Oncology, 2018, 45(1): 53-.

［1］侯健. 多发性骨髓瘤的免疫学研究［J］. 上海免疫学杂志, 2000, 5(4): 193196. DOI: 10.3969/j.issn.10012478.2000.04.001. ［2］ Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and downregulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia［J］. Proc Natl Acad Sci USA, 2002, 99(24): 1552415529. ［3］ Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis［J］. Proc Natl Acad Sci USA, 2008, 105 (35): 1288512890. DOI: 10.1073/pnas.0806202105. ［4］ Gutiérrez NC, Sarasquete ME, Misiewiczkrzeminska I, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling［J］. Leukemia, 2010, 24(3): 629637. DOI: 10.1038/leu.2009.274. ［5］ Yyusnita, Norsiah, Zakiah I, et al. MicroRNA (miRNA) expression profiling of peripheral blood samples in multiple myeloma patients using microarray［J］. Malays J Pathol, 2012, 34(2): 133143. ［6］ Chen L, Li C, Zhang R, et al. miR1792 cluster microRNAs confers tumorigenicity in multiple myeloma［J］. Cancer Lett, 2011, 309(1): 6270. DOI: 10.1016/j.canlet.2011.05.017. ［7］ Leone E, Morelli E, Di Martino MT, et al. Targeting miR21 inhibits in vitro and in vivo multiple myeloma cell growth［J］. Clin Cancer Res, 2013, 19(8): 20962106. DOI: 10.1158/10780432.CCR123325. ［8］ Amodio N, Leotta M, Bellizzi D, et al. DNAdemethylating and antitumor activity of synthetic miR29b mimics in multiple myeloma［J］. Oncotarget, 2012, 3(10): 12461258. ［9］ Raimondi L, De Luca A, Morelli E, et al. MicroRNAs: novel crossroads between myeloma cells and the bone marrow microenvironment［J］. Biomed Res Int, 2016, 2016: 6504593. DOI: 10.1155/2016/6504593. ［10］ Shen X, Guo Y, Yu J, et al. miRNA202 in bone marrow stromal cells affects the growth and adhesion of multiple myeloma cells by regulating B cellactivating factor［J］. Clin Exp Med, 2016, 16(3): 307316. DOI: 10.1007/s1023801503554. ［11］ Kubiczkova L, Kryukov F, Slaby O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance［J］. Haematologica, 2014, 99(3): 511518. DOI: 10.3324/haematol.2013.093500. ［12］ Jones CI, Zabolotskaya MV, King AJ, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma［J］. Br J Cancer, 2012, 107(12): 19871996. DOI: 10.1038/bjc.2012.525. ［13］ Zhang L, Cao D, Tang L, et al. A panel of circulating miRNAs as diagnostic biomarkers for screening multiple myeloma: a systematic review and metaanalysis［J］. Int J Lab Hematol, 2016, 38(6): 589599. DOI: 10.1111/ijlh.12560. ［14］ Yu J, Qiu X, Shen X, et al. miR202 expression concentration and its clinical significance in the serum of multiple myeloma patients［J］. Ann Clin Biochem, 2014, 51(Pt5): 543549. DOI: 10.1177/0004563213501155. ［15］ Qu X, Zhao M, Wu S, et al. Circulating microRNA 4835p as a novel biomarker for diagnosis survival prediction in multiple myeloma［J］. Med Oncol, 2014, 31(10): 219. DOI: 10.1007/s120320140219x. ［16］ Hao M, Zang M, Wendlandt E, et al. Low serum miR19a expression as a novel poor prognostic indicator in multiple myeloma［J］. Int J Cancer, 2015, 136(8): 18351844. DOI: 10.1002/ijc.29199. ［17］ Saleh EM, Wahab AH, Elhouseini ME, et al. Loss of heterozygosity at BRCA1, TP53, nm23 and other loci on chromosome 17q in human breast carcinoma［J］. J Egypt Natl Canc Inst, 2004, 16(1): 6268. ［18］ SimonKayser B, Scoul C, Renaudin K, et al. Molecular cloning and characterization of FBXO47, a novel gene containing an Fbox domain, located in the 17q12 band deleted in papillary renal cell carcinoma［J］. Genes Chromosomes Cancer, 2005, 43(1): 8394. ［19］ Rocci A, Hofmeister CC, Geyer S, et al. Circulating miRNA markers show promise as new prognosticators for multiple myeloma［J］. Leukemia, 2014, 28(9): 19221926. DOI: 10.1038/leu.2014.155. ［20］ Gao X, Zhang R, Qu X, et al. MiR15a, miR161 and miR1792 cluster expression are linked to poor prognosis in multiple myeloma［J］. Leuk Res, 2012, 36(12): 15051509. DOI: 10.1016/j.leukres.2012.08.021. ［21］ Huang JJ, Yu J, Li JY, et al. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma［J］. Med Oncol, 2012, 29(4): 24022408. DOI: 10.1007/s1203201202103. ［22］ Yoshizawa S, Ohyashiki JH, Ohyashiki M, et al. Downregulated plasma miR92a levels have clinical impact on multiple myeloma and related disorders［J］. Blood Cancer J, 2012, 2(1): e53. DOI: 10.1038/bc j.2011.51. ［23］ Sevcikova S, Kubiczkova L, Sedlarikova L, et al. Serum miR29a as a marker of multiple myeloma［J］. Leuk Lymphoma, 2013, 54(1): 189191. DOI: 10.3109/10428194.2012.704030. ［24］刘波, 李世龙, 尤建宇, 等. 探讨miRNA表达比在多发性骨髓瘤中的预测作用［J］. 中国实验诊断学, 2015, 19(2): 259261. ［25］ Munker R, Liu CG, Taccioli C, et al. MicroRNA profiles of drug resistant myeloma cell lines［J］. Acta Haematol, 2010, 123(4): 201204. DOI: 10.1159/000302889. ［26］ Palagani A, Op de Beeck K, Naulaerts S, et al. Ectopic microRNA1505p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cells［J］. PLoS One, 2014, 9(12): e113842. DOI: 10.1371/journal.pone.0113842. ［27］ Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy［J］. Leukemia, 2009, 23(1): 1024. DOI: 10.1038/leu.2008.259. ［28］ Ballabio E, Armesto M, Breeze CE, et al. Bortezomib action in multiple myeloma: microRNAmediated synergy (and miR27a/CDK5 driven sensitivity)?［J］. Blood Cancer J, 2012, 2: e83. DOI: 10.1038/bcj.2012.31. ［29］ Lffler D, BrockeHeidrich K, Pfeifer G, et al. Interleukin6 dependent survival of multiple myeloma cells involves the Stat3mediated induction of microRNA21 through a highly conserved enhancer［J］. Blood, 2007, 110(4): 13301333.

[1]	Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan. Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity， proliferation， and apoptosis of multiple myeloma cells [J]. Journal of International Oncology, 2024, 51(3): 129-136.
[2]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[3]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[4]	Zhang Yuxiao, Zhang Liansheng, Li Lijuan. Research status and application prospect of a novel immune checkpoint TIGIT in the immunotherapy of multiple myeloma [J]. Journal of International Oncology, 2023, 50(2): 122-125.
[5]	Zhao Jianhao, Duan Yanchao. Research progress in the pathogenesis of extramedullary disease in multiple myeloma [J]. Journal of International Oncology, 2023, 50(1): 55-59.
[6]	Gao Shan, Lu Minqiu, Shi Lei, Chu Bin, Fang Lijuan, Xiang Qiuqing, Wang Yutong, Ding Yuehua, Bao Li. Clinical efficacy and safety of ixazomib-based therapy in the treatment of relapsed or refractory multiple myeloma [J]. Journal of International Oncology, 2022, 49(5): 286-291.
[7]	Zhou Renbang, Zhang Zhongchuan, Xu Zhiyuan, Zhu Xunbing. MiR-219a-5p inhibits the proliferation, invasion and migration of osteosarcoma U2OS cells by negatively regulating HMGA2 [J]. Journal of International Oncology, 2022, 49(4): 193-198.
[8]	Jin Jiahui, Chen Cunhai, Ma Xuezhen. Effects of radiation-associated miRNA in radiotherapy for breast cancer [J]. Journal of International Oncology, 2022, 49(12): 735-738.
[9]	Jing Wenjun, Zhao Wenwen, Feng Qingqing, Zhao Wenfei, Zhao Lili, Zhang Xue, Wei Hongmei. Molecular basis and clinical prospect of the miR-34 family for the treatment of gastric cancer [J]. Journal of International Oncology, 2022, 49(11): 681-686.
[10]	Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin. Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis [J]. Journal of International Oncology, 2022, 49(1): 45-50.
[11]	Hong Anlan, Cao Meng, Wang Yan, Fang Fang. Research progress on lncRNAs as members of ceRNA network in melanoma [J]. Journal of International Oncology, 2022, 49(1): 61-64.
[12]	Liu Pei, Pu Jiaze, Huang Wen, Wang Fei. Expression differences of miR-200c, miR-19a and miR-155 in gefitinib sensitive and drug resistant NSCLC patients and their effects on prognosis [J]. Journal of International Oncology, 2021, 48(7): 409-414.
[13]	Wang Yang, Liu Qian, Long Hui, Wu Qingming. Research status of fecal detection for colorectal cancer markers [J]. Journal of International Oncology, 2021, 48(7): 441-444.
[14]	Sun Ruijie, Shan Ningning. Immune, targeted therapy and related issues of relapsed/refractory multiple myeloma [J]. Journal of International Oncology, 2021, 48(6): 381-384.
[15]	Cheng Yiming, Li Gang, Wang Zhenming, Lyu Qianwen, Li Shirong. Value of serum miR-196a-5p and miR-105-5p in differential diagnosis of benign and malignant pulmonary nodules [J]. Journal of International Oncology, 2021, 48(5): 282-286.

Application of circulating microRNAs in multiple myeloma

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments